{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:38:19Z","timestamp":1792028299005,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00428-021-03114-5","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T20:03:00Z","timestamp":1620331380000},"page":"467-473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Lenvatinib-related renal microangiopathy: a case series"],"prefix":"10.1007","volume":"480","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0715-6764","authenticated-orcid":false,"given":"Marco","family":"Delsante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Monroy-Trujillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naima","family":"Carter-Monroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avi Z.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"key":"3114_CR1","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.2147\/CMAR.S188316","volume":"11","author":"M Capozzi","year":"2019","unstructured":"Capozzi M, De Divitiis C, Ottaiano A, von Arx C, Scala S, Tatangelo F, Delrio P, Tafuto S (2019) Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment. Cancer Manag Res 11:3847\u20133860","journal-title":"Cancer Manag Res"},{"issue":"16","key":"3114_CR2","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1002\/cncr.29395","volume":"121","author":"ME Cabanillas","year":"2015","unstructured":"Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D et al (2015) A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer 121(16):2749\u20132756","journal-title":"Cancer"},{"key":"3114_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fonc.2017.00025","volume":"7","author":"M Tahara","year":"2017","unstructured":"Tahara M, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, Toda K, Enokida T, Minami H, Imamura Y et al (2017) Lenvatinib for anaplastic thyroid cancer. Front Oncol 7:25","journal-title":"Front Oncol"},{"issue":"6","key":"3114_CR4","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1158\/1078-0432.CCR-15-1354","volume":"22","author":"M Ikeda","year":"2016","unstructured":"Ikeda M, Okusaka T, Mitsunaga S, Ueno H, Tamai T, Suzuki T, Hayato S, Kadowaki T, Okita K, Kumada H (2016) Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma. Clin Cancer Res 22(6):1385\u20131394","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3114_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO et al (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372(7):621\u2013630","journal-title":"N Engl J Med"},{"issue":"15","key":"3114_CR6","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","volume":"16","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B et al (2015) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16(15):1473\u20131482","journal-title":"Lancet Oncol"},{"issue":"4","key":"3114_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2217\/fon.15.341","volume":"12","author":"G Oikonomopoulos","year":"2016","unstructured":"Oikonomopoulos G, Aravind P, Sarker D (2016) Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma? Future Oncol 12(4):465\u2013476","journal-title":"Future Oncol"},{"issue":"6535","key":"3114_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/376062a0","volume":"376","author":"F Shalaby","year":"1995","unstructured":"Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376(6535):62\u201366","journal-title":"Nature"},{"issue":"1","key":"3114_CR9","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.1038\/ncb0102-e2","volume":"4","author":"MJ Karkkainen","year":"2002","unstructured":"Karkkainen MJ, M\u00e4kinen T, Alitalo K (2002) Lymphatic endothelium: a new frontier of metastasis research. Nat Cell Biol 4(1):E2-5","journal-title":"Nat Cell Biol"},{"issue":"6","key":"3114_CR10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/nrneph.2015.15","volume":"11","author":"C Porta","year":"2015","unstructured":"Porta C, Cosmai L, Gallieni M, Pedrazzoli P, Malberti F (2015) Renal effects of targeted anticancer therapies. Nat Rev Nephrol 11(6):354\u2013370","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"3114_CR11","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/ki.2015.30","volume":"87","author":"MA Perazella","year":"2015","unstructured":"Perazella MA, Izzedine H (2015) New drug toxicities in the onco-nephrology world. Kidney Int 87(5):909\u2013917","journal-title":"Kidney Int"},{"issue":"3","key":"3114_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/17512433.2020.1734450","volume":"13","author":"W Zhang","year":"2020","unstructured":"Zhang W, Feng LJ, Teng F, Li YH, Zhang X, Ran YG (2020) Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials. Expert Rev Clin Pharmacol 13(3):311\u2013320","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"3114_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/17425255.2018.1461839","volume":"14","author":"S Cavalieri","year":"2018","unstructured":"Cavalieri S, Cosmai L, Genderini A, Nebuloni M, Tosoni A, Favales F, Pistillo P, Bergamini C, Bossi P, Licitra L et al (2018) Lenvatinib-induced renal failure: two first-time case reports and review of literature. Expert Opin Drug Metab Toxicol 14(4):379\u2013385","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"3114_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12882-018-1074-3","volume":"19","author":"Y Furuto","year":"2018","unstructured":"Furuto Y, Hashimoto H, Namikawa A, Outi H, Takahashi H, Horiuti H, Honda K, Shibuya Y (2018) Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report. BMC Nephrol 19(1):273","journal-title":"BMC Nephrol"},{"key":"3114_CR15","first-page":"6927639","volume":"2018","author":"K Fleming","year":"2018","unstructured":"Fleming K, McGuinness J, Kipgen D, Glen H, Spiliopoulou P (2018) A case of lenvatinib-induced focal segmental glomerulosclerosis (FSGS) in metastatic medullary thyroid cancer. Case Rep Oncol Med 2018:6927639","journal-title":"Case Rep Oncol Med"},{"issue":"3","key":"3114_CR16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1159\/000494080","volume":"11","author":"Y Hyogo","year":"2018","unstructured":"Hyogo Y, Kiyota N, Otsuki N, Goto S, Imamura Y, Chayahara N, Toyoda M, Nibu KI, Hyodo T, Hara S et al (2018) Thrombotic microangiopathy with severe proteinuria induced by lenvatinib for radioactive iodine-refractory papillary thyroid carcinoma. Case Rep Oncol 11(3):735\u2013741","journal-title":"Case Rep Oncol"},{"issue":"11","key":"3114_CR17","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH et al (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358(11):1129\u20131136","journal-title":"N Engl J Med"},{"issue":"1","key":"3114_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.2353\/ajpath.2010.091008","volume":"177","author":"P Boor","year":"2010","unstructured":"Boor P, van Roeyen CR, Kunter U, Villa L, B\u00fccher E, Hohenstein B, Hugo CP, Eriksson U, Satchell SC, Mathieson PW et al (2010) PDGF-C mediates glomerular capillary repair. Am J Pathol 177(1):58\u201369","journal-title":"Am J Pathol"},{"issue":"1","key":"3114_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1172\/JCI86418","volume":"127","author":"LS Keir","year":"2017","unstructured":"Keir LS, Firth R, Aponik L, Feitelberg D, Sakimoto S, Aguilar E, Welsh GI, Richards A, Usui Y, Satchell SC et al (2017) VEGF regulates local inhibitory complement proteins in the eye and kidney. J Clin Invest 127(1):199\u2013214","journal-title":"J Clin Invest"},{"key":"3114_CR20","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0.\u00a0https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed Jan 2021"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-021-03114-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-021-03114-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-021-03114-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T12:08:48Z","timestamp":1649246928000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-021-03114-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["3114"],"URL":"https:\/\/doi.org\/10.1007\/s00428-021-03114-5","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,6]]},"assertion":[{"value":"17 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Johns Hopkins Medicine Institutional Review Board (IRB number 00090103).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}